Grant MacLean

Title: Grant MacLean: Innovator in Monoclonal Antibody Research

Introduction

Grant MacLean is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies. His work focuses on creating innovative solutions for cancer detection and treatment.

Latest Patents

Grant MacLean holds a patent for "Carcinoma-marking monoclonal antibodies elicited with synthetic." This patent describes monoclonal antibodies produced after immunization with a synthetic antigen that bears the structure Gal (beta 1-3) GalNac beta-glycosidically linked to a carrier moiety. These antibodies are useful as carcinoma markers. The patent also details radioimmunoimaging agents in which such antibodies are tagged with radiometals or radiohalogens. Notably, the radiolabeled monoclonal antibody 155H.7, elicited by this antigen, rapidly localizes and persists in tumor tissues, demonstrating its utility as a tumor imaging agent. Grant MacLean has 1 patent to his name.

Career Highlights

Grant MacLean has worked at Biomira, Inc., where he has been instrumental in advancing research in monoclonal antibodies. His innovative approaches have contributed to the development of new diagnostic tools for cancer.

Collaborations

Throughout his career, Grant has collaborated with notable colleagues, including Connie J. Turner and Bryan M. Longenecker. These partnerships have fostered a collaborative environment that enhances research outcomes.

Conclusion

Grant MacLean's contributions to the field of monoclonal antibodies have paved the way for advancements in cancer detection and treatment. His innovative work continues to impact the biomedical research community positively.